I agree with what was said. In our system we have the freedom of choice for the prescriber; there are thus plenty of options for the prescriber to prescribe whatever he or she feels is necessary for the patient.
It's not as if there have been companies leaving the markets, with the system freed up with generics and given our ability to tender and various insurance companies participating in the tender. Even in the generic space, several providers are engaging in competition.
When it comes to new products, the Netherlands seems to be relatively early in the launch sequences of companies, and we haven't yet had shortages of new products not yet introduced into the Netherlands.
I don't feel that patients are missing out on products they should have had.